United States Securities And Exchange Commission
                              Washington, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 Current Report
                     Pursuant To Section 13 or 15(d) of the
                         Securities Exchange Act Of 1934


Date of Report (Date of earliest event reported):         May 16, 2003
                                                     ---------------------------


                         Provectus Pharmaceuticals, Inc.
               (Exact Name of Registrant as Specified in Charter)


               Nevada                      0-9410              90-0031917
--------------------------------------------------------------------------------
 (State or Other Jurisdiction of         (Commission        (I.R.S. Employer
 Incorporation or Organization)         File Number)     Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee           37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)                (Zip Code)

Registrant's telephone number, including area code:         865/769-4011
                                                       -------------------------


          (Former Name or Former Address, if Changed Since Last Report)


<PAGE>
Item 5. Other Events.

     As  previously  reported  in the  Quarterly  Report on Form  10-QSB for the
fiscal quarter ended March 31, 2003 filed by Provectus Pharmaceuticals,  Inc., a
Nevada  corporation (the "Company") with the Securities and Exchange  Commission
(the  "SEC")  on May 9,  2003,  a suit was  filed by Kelly  Adams,  on behalf of
himself  and  "as   representative   of  certain   Stockholders   of   Provectus
Pharmaceuticals,  Inc., a Nevada  corporation,  " on April 17, 2003 in the Third
Judicial  District Court, Salt Lake County,  Utah (the "Court").  The suit names
the Company's former  subsidiary  Provectus  Pharmaceuticals,  Inc., a Tennessee
corporation  ("PPI")  and  Michael L.  Labertew,  an attorney in Salt Lake City,
Utah,  as   defendants,   and  seeks  to  rescind  the  Agreement  and  Plan  of
Reorganization  dated April 22, 2002 by which the Company acquired PPI (with PPI
becoming a wholly owned subsidiary of the Company) and PPI's former stockholders
acquired majority ownership of our common stock.

     As previously  reported,  on April 29, 2003,  without giving the Company or
PPI notice of the motion or an  opportunity  to respond to it, the Court granted
Mr.  Adams's  ex parte  motion for a  temporary  restraining  order (the  "TRO")
preventing  PPI from  issuing  additional  shares of stock  for a 10-day  period
commencing on April 29, 2003. Mr. Adams also moved for a preliminary  injunction
that, if granted,  would have imposed the same restrictions until the completion
of the proceedings.

     On May 12, 2003,  PPI filed its  Consolidated  Memorandum  in Opposition to
Plaintiff's  Motion for  Preliminary  Injunction  and  Memorandum  in Support of
Motion to Dismiss in response to the entry of the TRO and Mr. Adams's motion for
a preliminary injunction.

     On May 13, 2003, the Court conditionally lifted the TRO against the Company
pending a hearing scheduled for May 16, 2003.

     On May 16,  2003,  the Court  held a hearing  on Mr.  Adams's  motion for a
preliminary  injunction.  At the  hearing,  the Court  denied  the  motion for a
preliminary  injunction  citing Mr. Adam's failure to meet his burden under Utah
law.

     On May 21,  2003,  the  Court  entered a written  order  memorializing  its
earlier ruling on May 16, 2003,  which  dissolved the TRO and denied Mr. Adams's
preliminary  injunction  motion. In dissolving the TRO and refusing to grant the
preliminary  injunction,  the Court cited Mr. Adams's inability to establish any
significant  harm that would result to Mr. Adams if the  preliminary  injunction
were not granted,  the significant  harm that would result to the Company if the
preliminary  injunction  were  granted,  and  Mr.  Adams's  failure  to  show  a
substantial  likelihood that he would prevail on the merits of his lawsuit,  The
Court  specifically  cited Mr. Adams's failure to show a substantial  likelihood
that he would  prevail on the issues of (i) whether he had  standing as a proper
plaintiff to assert his alleged cause of action and (ii) whether  rescission was
an available and  appropriate  remedy in this case. The Court's order allows Mr.
Adams to amend his complaint.

     We continue to believe  that the claims made by Mr.  Adams and the "certain
Stockholders" in their complaint are groundless. In view of the positive results
of the May 16, 2003 hearing and the Court's May 21, 2003 order,  we have entered
into settlement  negotiations  with a view toward resolving this litigation in a
manner  satisfactory  to the Company.  However,  there can be no assurance  that
these settlement  negotiations  will result in a satisfactory  resolution of the
litigation  filed  by  Mr.  Adams.  If  the  settlement   negotiations  are  not
successful,  we intend to continue  contesting  the suit  vigorously,  including
seeking a hearing on the pending motion to dismiss.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

(c)      Exhibits.

         None.

                                       1
<PAGE>
                                   Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                              Provectus Pharmaceuticals, Inc.


Dated:   May 22, 2003                         By: /s/Daniel R. Hamilton
                                                  ----------------------------
                                                  Daniel R. Hamilton
                                                  Chief Financial Officer


                                       2
[{"type": "8-K", "sequence": "1", "filename": "provectus8k052203.txt", "description": "CURRENT REPORT", "secsgml_size_bytes": 6181}]
{"company-data": {"conformed-name": "PROVECTUS PHARMACEUTICALS INC", "cik": "0000315545", "assigned-sic": "2834", "irs-number": "900031917", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-09410", "film-number": "03716687"}, "business-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931", "phone": "865-769-4011"}, "mail-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931"}, "former-company": [{"former-conformed-name": "ZAMAGE DIGITAL IMAGING INC", "date-changed": "20011126"}, {"former-conformed-name": "SPM GROUP INC", "date-changed": "19920703"}]}
United States Securities And Exchange Commission
                              Washington, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 Current Report
                     Pursuant To Section 13 or 15(d) of the
                         Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported):         May 16, 2003
                                                     ---------------------------

                         Provectus Pharmaceuticals, Inc.
               (Exact Name of Registrant as Specified in Charter)

               Nevada                      0-9410              90-0031917
--------------------------------------------------------------------------------
 (State or Other Jurisdiction of         (Commission        (I.R.S. Employer
 Incorporation or Organization)         File Number)     Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee           37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)                (Zip Code)

Registrant's telephone number, including area code:         865/769-4011
                                                       -------------------------

          (Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.

     As  previously  reported  in the  Quarterly  Report on Form  10-QSB for the
fiscal quarter ended March 31, 2003 filed by Provectus Pharmaceuticals,  Inc., a
Nevada  corporation (the "Company") with the Securities and Exchange  Commission
(the  "SEC")  on May 9,  2003,  a suit was  filed by Kelly  Adams,  on behalf of
himself  and  "as   representative   of  certain   Stockholders   of   Provectus
Pharmaceuticals,  Inc., a Nevada  corporation,  " on April 17, 2003 in the Third
Judicial  District Court, Salt Lake County,  Utah (the "Court").  The suit names
the Company's former  subsidiary  Provectus  Pharmaceuticals,  Inc., a Tennessee
corporation  ("PPI")  and  Michael L.  Labertew,  an attorney in Salt Lake City,
Utah,  as   defendants,   and  seeks  to  rescind  the  Agreement  and  Plan  of
Reorganization  dated April 22, 2002 by which the Company acquired PPI (with PPI
becoming a wholly owned subsidiary of the Company) and PPI's former stockholders
acquired majority ownership of our common stock.

     As previously  reported,  on April 29, 2003,  without giving the Company or
PPI notice of the motion or an  opportunity  to respond to it, the Court granted
Mr.  Adams's  ex parte  motion for a  temporary  restraining  order (the  "TRO")
preventing  PPI from  issuing  additional  shares of stock  for a 10-day  period
commencing on April 29, 2003. Mr. Adams also moved for a preliminary  injunction
that, if granted,  would have imposed the same restrictions until the completion
of the proceedings.

     On May 12, 2003,  PPI filed its  Consolidated  Memorandum  in Opposition to
Plaintiff's  Motion for  Preliminary  Injunction  and  Memorandum  in Support of
Motion to Dismiss in response to the entry of the TRO and Mr. Adams's motion for
a preliminary injunction.

     On May 13, 2003, the Court conditionally lifted the TRO against the Company
pending a hearing scheduled for May 16, 2003.

     On May 16,  2003,  the Court  held a hearing  on Mr.  Adams's  motion for a
preliminary  injunction.  At the  hearing,  the Court  denied  the  motion for a
preliminary  injunction  citing Mr. Adam's failure to meet his burden under Utah
law.

     On May 21,  2003,  the  Court  entered a written  order  memorializing  its
earlier ruling on May 16, 2003,  which  dissolved the TRO and denied Mr. Adams's
preliminary  injunction  motion. In dissolving the TRO and refusing to grant the
preliminary  injunction,  the Court cited Mr. Adams's inability to establish any
significant  harm that would result to Mr. Adams if the  preliminary  injunction
were not granted,  the significant  harm that would result to the Company if the
preliminary  injunction  were  granted,  and  Mr.  Adams's  failure  to  show  a
substantial  likelihood that he would prevail on the merits of his lawsuit,  The
Court  specifically  cited Mr. Adams's failure to show a substantial  likelihood
that he would  prevail on the issues of (i) whether he had  standing as a proper
plaintiff to assert his alleged cause of action and (ii) whether  rescission was
an available and  appropriate  remedy in this case. The Court's order allows Mr.
Adams to amend his complaint.

     We continue to believe  that the claims made by Mr.  Adams and the "certain
Stockholders" in their complaint are groundless. In view of the positive results
of the May 16, 2003 hearing and the Court's May 21, 2003 order,  we have entered
into settlement  negotiations  with a view toward resolving this litigation in a
manner  satisfactory  to the Company.  However,  there can be no assurance  that
these settlement  negotiations  will result in a satisfactory  resolution of the
litigation  filed  by  Mr.  Adams.  If  the  settlement   negotiations  are  not
successful,  we intend to continue  contesting  the suit  vigorously,  including
seeking a hearing on the pending motion to dismiss.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

(c)      Exhibits.

         None.

                                       1
Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                              Provectus Pharmaceuticals, Inc.

Dated:   May 22, 2003                         By: /s/Daniel R. Hamilton
                                                  ----------------------------
                                                  Daniel R. Hamilton
                                                  Chief Financial Officer

                                       2